In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRISPR Therapeutics AG

www.crisprtx.com

Latest From CRISPR Therapeutics AG

Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna

Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.

Financing Business Strategies

Sickle Cell Disease Market Snapshot: "The Time Has Come"

Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.

Blood & Coagulation Disorders Launches

Novo Nordisk, Bluebird Targeting ‘Lifelong’ Gene Therapies

Novo Nordisk and bluebird bio will jointly develop genome editing treatments for genetic diseases, beginning with hemophilia.
Commercial Companies

Start-Up Quarterly Statistics: Financings Fell 17% To $2.84bn In Q2

A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Hepatic (Liver)
  • Immune Disorders
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • CRISPR Therapeutics AG
  • Senior Management
  • Samarth Kulkarni, PhD, CEO
    Michael Tomsicek, CFO
    Rodger Novak, PhD, Pres.
    Lawrence Klein, PhD, CBO
    Tony Ho, MD, Head, R&D
  • Contact Info
  • CRISPR Therapeutics AG
    Phone: 41 561 32 77
    Baarerstrasse 14
    Zug, V8 CH-6300
    Switzerland
UsernamePublicRestriction

Register